Y-90 PHYSICS: BETA RADIATION,
HALF-LIFE, AND MICROSPHERE SAFETY
A clear, patient-facing explanation of the physics that makes Y-90 radioembolization work โ and why the use of radioactive microspheres is safer for the patient and their family than many patients initially expect.
analyticsAt a Glance
- check_circleY-90 emits beta radiation โ high-energy electrons with a very short tissue range (~2.5 mm average)
- check_circlePure beta emitter: no gamma radiation, no significant external exposure risk to family or contacts
- check_circle64.1-hour half-life means radioactivity is essentially complete within 11 days of treatment
- check_circleMicrospheres are permanent implants โ they remain lodged in tumour vasculature indefinitely
What Is Yttrium-90 (Y-90)?
Yttrium-90 is an unstable radioactive isotope of the element yttrium. It is produced by the radioactive decay of strontium-90 and is purified for medical use as a pure beta emitter โ meaning it releases only beta particles (electrons) during its decay, with no accompanying gamma photons. This characteristic is central to its safety profile in clinical use.
โThe physics of Y-90 are almost ideally matched to the clinical problem of liver tumour treatment โ short range, right energy, right half-life.โ
Beta Emission โ Not Gamma
Y-90 decays by emitting beta particles (high-energy electrons). Beta particles are absorbed within a few millimetres of tissue and cannot penetrate the patient's body wall โ meaning external radiation exposure to family members, caregivers, or healthcare workers is negligibly small. This contrasts sharply with gamma-emitting isotopes (like iodine-131) which require isolation precautions.
Y-90 โ Zirconium-90 (Stable)
Y-90 decays to zirconium-90 (Zr-90), which is completely stable and non-radioactive. There is no decay chain producing further radioactive daughters โ once Y-90 has decayed, the microspheres remaining in the tumour contain only inert zirconium and the glass or resin carrier material.
Y-90 Physical Properties โ Reference Table
A complete reference of the key physical characteristics of yttrium-90 relevant to its use in radioembolization. These properties define both the therapeutic effect and the safety profile.
| Property | Value | Clinical Relevance |
|---|---|---|
| Emission type | Pure beta (ฮฒโป) emitter | No gamma emission โ minimal external radiation risk to patient contacts |
| Maximum beta energy | 2.28 MeV | High energy sufficient for tumour cell DNA double-strand break induction |
| Mean beta energy | 0.934 MeV | Energy deposited as heat and ionisation within ~2.5 mm radius of each microsphere |
| Physical half-life | 64.1 hours (~2.67 days) | ~90% of total radiation dose delivered within the first 11 days (5 half-lives) |
| Average tissue penetration | ~2.5 mm (mean); max ~11 mm | Limits radiation to immediate tumour bed โ short enough to spare adjacent bile ducts and vessels |
| Decay product | Zirconium-90 (stable, non-toxic) | No radioactive daughters โ microspheres become inert after Y-90 decay |
| Bremsstrahlung radiation | Very low energy secondary X-rays | Permits post-treatment PET/Bremsstrahlung SPECT imaging for distribution verification |
What Are the Microspheres Made Of?
The Y-90 radioisotope is not injected in liquid form โ it is embedded within or bound to tiny spheres (microspheres) that lodge in the small tumour arterioles after injection, ensuring the radioactive material stays precisely at the target site and is not distributed systemically.
Glass Microspheres (TheraSphere)
TheraSphere (BTG/Boston Scientific) uses yttrium-90 permanently incorporated into borosilicate glass microspheres. Glass spheres are very small (20โ30 ยตm diameter) and highly radioactive โ higher activity per sphere allows fewer microspheres per dose, with lower embolization effect and stronger radiation dose per sphere.
Resin Microspheres (SIR-Spheres)
SIR-Spheres (Sirtex Medical) uses Y-90 attached to biocompatible resin microspheres. Resin spheres are larger (20โ60 ยตm) and individually less radioactive โ requiring a higher number of microspheres per dose. They produce a more pronounced embolic effect on top of the radiation delivery.
Microsphere Size Matters Clinically
Microsphere size determines how far into the tumour vasculature the particles travel before lodging. Smaller spheres (TheraSphere) penetrate further into the tumour microvasculature; larger spheres (SIR-Spheres) tend to lodge in larger arterioles proximal to the tumour. This influences dose distribution and the embolic contribution to tumour kill.
Permanent Implants
Both glass and resin microspheres are permanent โ they are not biodegradable or absorbable after implantation. After Y-90 decays, inert glass or resin particles remain lodged within the tumour vasculature indefinitely, but they are biologically inert and do not cause ongoing harm.
How Y-90 Radiation Is Delivered Over Time
Y-90 does not deliver its full dose instantly โ it decays exponentially, with the majority of dose delivered in the first few days and essentially complete by day 11.
- 1
Day 0 โ Microsphere Implantation
Microspheres are injected and immediately lodge in tumour arterioles. Y-90 begins emitting beta radiation from the moment of implantation. The injected activity (in gigabecquerels, GBq) represents the total dose to be delivered.
- 2
Days 0โ3 โ Peak Dose Rate
Y-90 is at its maximum activity immediately after implantation. The first 64.1 hours (one half-life) deliver 50% of the total prescribed radiation dose โ the highest daily dose rate the tumour tissue experiences.
- 3
Days 3โ7 โ Ongoing Dose Delivery
Activity halves with each 64.1-hour period. By day 7 (approximately 2.5 half-lives), approximately 83% of the total dose has been delivered. The patient's physical radiation levels are low enough at this stage that most normal activities can be resumed.
- 4
Days 7โ11 โ Completion of Clinically Relevant Dose
By day 11 (approximately 4 half-lives), over 94% of the total radiation dose has been delivered. Beyond this point, remaining activity is clinically negligible.
- 5
Beyond Day 11 โ Stable Inert Implant
After approximately 5 half-lives (~11 days), the remaining Y-90 activity is less than 3% of the original dose โ effectively zero from a clinical radiation safety standpoint. The microspheres persist as inert implants but carry no further radiological significance.
Y-90 Physics โ Key Numbers at a Glance
The most important physical parameters for patients and families understanding Y-90 radioembolization safety.
- 2.5 mmAverage tissue penetration depth of Y-90 beta particlesThis short range is the physical basis for TARE's selectivity โ radiation is deposited almost entirely within the tumour and not in surrounding normal liver or adjacent organs.
- 64.1 hrsPhysical half-life of Y-90Each 64.1 hours, half the remaining activity decays. Five half-lives (~11 days) results in <3% of original activity remaining.
- 0 GyExternal gamma radiation dose to patient contacts โ Y-90 is a pure beta emitterNo gamma rays means no shielding requirements and no radiation risk to family members, children, or caregivers after treatment.
More from the TARE / Y-90 Resource Library
Continue exploring Y-90 radioembolization โ from platform comparisons to the pre-treatment workup and dosimetry.
Frequently Asked Questions About Y-90 Physics and Safety
Am I radioactive after Y-90 treatment and should I avoid my family?
Y-90 is a pure beta emitter โ it does not emit gamma radiation. Beta particles are completely absorbed within a few millimetres of the patient's skin and cannot reach family members. There is no need for isolation after Y-90 radioembolization. Most centres advise simple common-sense precautions for the first few days: avoid prolonged close contact with pregnant women and young children (< 2 years), maintain normal social distance when possible, and do not share bodily fluids. You can sleep in the same bed with your partner, eat with your family, and live normally within 24โ48 hours of treatment.
Can Y-90 microspheres move from the tumour to other organs?
The primary safety concern in TARE is non-target microsphere deposition โ microspheres travelling through abnormal vascular connections to the lungs (hepatopulmonary shunting) or to the gastrointestinal tract (via aberrant vessels). This is why the pre-treatment workup โ including the MAA scan โ is mandatory: it quantifies lung shunting and identifies aberrant vessels before treatment. Properly selected patients with acceptable shunt fractions and no significant aberrant vessels have very low rates of significant non-target deposition.
What is bremsstrahlung radiation and is it safe?
Bremsstrahlung ('braking radiation') is secondary X-radiation produced when high-energy beta particles decelerate as they interact with surrounding tissue. Y-90 produces a small amount of bremsstrahlung radiation โ enough to be detected by gamma cameras (used for post-treatment distribution imaging) but not enough to constitute a meaningful external radiation hazard to contacts. Bremsstrahlung levels from Y-90 are orders of magnitude lower than gamma emission from isotopes like technetium-99m used in routine nuclear medicine scans.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About TARE Safety or Eligibility? CancerFax Can Help.
CancerFax reviews your liver tumour records and coordinates eligibility assessment at specialist Y-90 centres in China and India โ including radiation safety planning and dosimetry review.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist and interventional radiologist before making treatment decisions.